

PRESS RELEASE

19 October 2023 17:00:00 CEST

Bulletin from EXTRAORDINARY GENERAL MEETING in Senzime AB (publ)

The extraordinary general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the "Company") was held on 19 October 2023, whereby the shareholders primarily resolved on the following matter.

Resolution on the approval of the board of directors' resolution on a directed share issue

In accordance with previously published information, the board of directors resolved 25 September 2023 on a directed issue of shares, subject to the subsequent approval of the extraordinary general meeting. The general meeting resolved today to approve the board of directors' resolution on a directed issue of a maximum of 18,000,000 shares. The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong to Nordic Issuing AB, for re-transfer to a limited number of investors pursuant to existing agreements.

The Company's share capital will increase by a maximum of SEK 2,250,000 through a directed issue of a maximum of 18,000,000 shares. The subscription prices for the shares in the new issue is SEK 0.125 per share, corresponding to the quota value for the Company's share. However, the price to be used at re-transfer to investor shall correspond to SEK 6.50 per share. Subscription with subscription rights shall be made by cash payment not later than 20 October 2023.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Bulletin from EXTRAORDINARY GENERAL MEETING in Senzime AB (publ)